News stories about Enzymotec (NASDAQ:ENZY) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzymotec earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.8540055689917 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several research firms have weighed in on ENZY. ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. Zacks Investment Research cut shares of Enzymotec from a “hold” rating to a “sell” rating in a research report on Monday, May 22nd. One equities research analyst has rated the stock with a sell rating and three have issued a hold rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $8.00.

Enzymotec (NASDAQ ENZY) opened at 11.50 on Friday. Enzymotec has a 52-week low of $5.20 and a 52-week high of $12.35. The stock’s market capitalization is $263.91 million. The firm’s 50-day moving average is $9.39 and its 200 day moving average is $8.73.

Enzymotec (NASDAQ:ENZY) last issued its earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The firm had revenue of $13 million during the quarter, compared to the consensus estimate of $12.78 million. During the same period in the previous year, the company posted $0.04 EPS. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. On average, equities analysts forecast that Enzymotec will post $0.14 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-enzymotec-enzy-share-price/1535187.html.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.

Insider Buying and Selling by Quarter for Enzymotec (NASDAQ:ENZY)

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.